Your browser doesn't support javascript.
loading
Time for radioimmunotherapy: an overview to bring improvements in clinical practice.
Leaman Alcibar, O; Candini, D; López-Campos, F; Albert Antequera, M; Morillo Macías, V; Conde, A J; Rodríguez Pérez, A; Hervás Morón, A; Contreras Martínez, J; Ferrer Albiach, C; Navarro Aguilar, S; Rodríguez-Ruiz, M E.
Afiliación
  • Leaman Alcibar O; Radiation Oncology Department, Central University Hospital of Defence Gómez Ulla, Madrid, Spain. olwenleaman@gmail.com.
  • Candini D; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
  • López-Campos F; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
  • Albert Antequera M; Radiation Oncology Department, La Ribera University Hospital, Valencia, Spain.
  • Morillo Macías V; Radiation Oncology Department, General Hospital in Castellón de la Plana, Castellón, Spain.
  • Conde AJ; Radiation Oncology Department, The University and Polytechnic La Fe Hospital, Valencia, Spain.
  • Rodríguez Pérez A; Radiation Oncology Department, Internacional Ruber Hospital, Madrid, Spain.
  • Hervás Morón A; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
  • Contreras Martínez J; Radiation Oncology Department, Málaga Hospital, Málaga, Spain.
  • Ferrer Albiach C; Radiation Oncology Department, General Hospital in Castellón de la Plana, Castellón, Spain.
  • Navarro Aguilar S; Radiation Oncology Department, Oncology and Radiotherapy Institut, Ricardo Palma Clinic, Lima, Peru.
  • Rodríguez-Ruiz ME; Radiation Oncology Department, University of Navarra Clinic and CIMA, Navarra, Spain.
Clin Transl Oncol ; 21(8): 992-1004, 2019 Aug.
Article en En | MEDLINE | ID: mdl-30644044
Harnessing the patient's own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical "checkpoints" that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient's own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioinmunoterapia / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Transl Oncol Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioinmunoterapia / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Transl Oncol Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia